GlassScriptPhysician profile
Kyriakos Kirou
NPI 1457314973
$19,036.49
in general payments reported to CMS, 2019-2025
12 companies · $9,557 in 2025
The $9,557 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.71 · 2023: $5,110 · 2024: $4,352 · 2025: $9,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $2,709 · Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,152.50 |
| Travel and Lodging | $2,708.92 |
| Food and Beverage | $1,157.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $7,120.45 | 2024-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $4,926.39 | 2023 | Saphnelo |
| Tanabe Pharma America, INC. | $2,450.00 | 2025 | |
| Pfizer INC. | $2,102.68 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $1,093.50 | 2025 | |
| Ucb Sa | $979.15 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $218.02 | 2021-2025 | |
| Ucb, INC. | $98.88 | 2023 | |
| Novartis Pharmaceuticals Corporation | $47.42 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyriakos Kirou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.